Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| PTLE | Ptl | $8.10 | $3.83 | 89.70% | 56.8K | $27M | $4.00$156.00 |
| AHMA | Ambitions Enterprise Management L.l.c | $7.25 | $2.71 | 59.52% | 738.8K | $134M | $4.00$39.50 |
| BIAF | bioAffinity Technologies | $4.14 | $1.41 | 51.65% | 331.9K | $12M | $0.69$46.53 |
| AIFF | Firefly Neuroscience | $2.22 | $0.69 | 45.08% | 15.1M | $22M | $0.62$5.10 |
| UGRO | Urban-gro | $3.13 | $0.95 | 43.58% | 84.1M | $1.6M | $2.02$19.76 |
| ALDX | Aldeyra Therapeutics | $2.21 | $0.40 | 22.10% | 67.1K | $109M | $1.07$6.81 |
| SATL | Satellogic | $4.34 | $0.75 | 20.89% | 192.1K | $513M | $1.26$5.93 |
| RDIB | Reading International | $9.61 | $1.61 | 20.11% | 2.3K | $182M | $6.70$17.40 |
| APGE | Apogee Therapeutics | $79.11 | $13.07 | 19.79% | 89.1K | $4.6B | $26.20$84.56 |
| CV | CapsoVision | $8.21 | $1.34 | 19.50% | 526.6K | $322M | $3.43$15.37 |
| SMX | Smx (Security Matters) Public | $9.10 | $1.40 | 18.18% | 7.7K | $17M | $7.67$30,548.63 |
| ALLO | Allogene Therapeutics | $2.44 | $0.37 | 17.87% | 77.2K | $505M | $0.86$2.80 |
| AXTI | AXT | $63.76 | $9.52 | 17.55% | 226.6K | $3.0B | $1.13$64.27 |
| ULH | Universal Logistics | $20.63 | $3.07 | 17.45% | 1.8K | $466M | $12.78$30.76 |
| SUPX | SuperX Ai Technology | $9.98 | $1.45 | 17.00% | 10.2K | $229M | $6.91$76.50 |
| XPEG | Themes ETF Trust - Leverage Shares 2x Long Xpev Daily ETF | $11.65 | $1.59 | 15.78% | 22.7K | - | $8.00$15.89 |
| MRLN | Merlin | $9.26 | $1.26 | 15.75% | 220.9K | $270M | $6.51$13.21 |
| GLWG | Themes ETF Trust - Leverage Shares 2x Long Glw Daily ETF | $15.99 | $2.17 | 15.70% | 149.1K | - | $13.67$17.43 |
| TERG | Themes ETF Trust - Leverage Shares 2x Long Ter Daily ETF | $42.94 | $5.66 | 15.17% | 19.8K | - | $12.19$55.21 |
| IHRT | iHeartMedia | $2.87 | $0.38 | 15.06% | 324.6K | $375M | $0.95$5.44 |
| AGCC | Agencia Comercial Spirits | $16.14 | $2.09 | 14.88% | 2.3K | $483M | $3.66$24.98 |
| CIFG | Themes ETF Trust - Leverage Shares 2x Long Cifr Daily ETF | $7.12 | $0.89 | 14.28% | 59.8K | - | $5.46$16.08 |
| YDES | Yd Bio | $6.23 | $0.77 | 14.01% | 14.8K | $385M | $5.30$31.00 |
| GDC | Gd Culture Group | $2.64 | $0.32 | 13.79% | 3.3K | $133M | $1.80$9.92 |
| HSPTU | Horizon Space Acquisition II Corp. | $7.24 | -$4.37 | -37.64% | 3 | $66M | $7.24$13.50 |
Related Articles
Featured Article
1 Small-Cap Stock I'd Buy Before GLBE in 2026
Marc Guberti|Jan 8, 2026
Global-E Online is a small company trying to carve out a niche in the competitive e-commerce space, while AXT is a small semiconductor player that already has a lead in an emerging opportunity.
A Quiet AI Stock -- SuperX AI Technology (SUPX) -- Is Up Over 770% in 2025. Here's 1 Key Reason Why It's Getting Attention.
Selena Maranjian|Nov 24, 2025
This company is a very early-stage AI business. It could skyrocket over the coming years, but it might not.
This Undervalued Stock Is Up Over 1,000% This Year. Here's 1 Key Reason Why the Run May Continue
Manali Pradhan, CFA|Nov 9, 2025
Picking a small stake in early stage AI infrastructure players can prove a smart move for investors with above-average risk appetite.
This Small AI Stock Has Outpaced Nvidia. 1 Reason Why It's Still Rising.
Stefon Walters|Oct 22, 2025
This company's path to profitability is getting a lot clearer.
4 Companies That Could Upend the Pharma Industry
James Halley|Jul 29, 2020
Their groundbreaking research on CAR T-cell therapies could revolutionize how certain cancers are treated in the future.
3 Turnaround Stocks to Consider for the Long Term
Bradley Freeman|Jul 16, 2020
How these three companies can be big winners.
2 Great Stocks Trading for Under $10 (or Around $10) a Share
Bradley Freeman|Jul 8, 2020
Interested in low-priced shares of companies with high potential? Consider these arguments for investing in iHeartMedia and Bed Bath & Beyond.
3 Reasons I'm Crushing on iHeartMedia
Bradley Freeman|Jun 15, 2020
Why iHeartMedia is a good investment today.
2 Big Biotech Stock Upgrades: Can They Reach These Targets?
Cory Renauer|May 5, 2019
Investment-bank analysts think these drugmakers are worth a lot more than the stock market does at the moment.
